Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Kelly, William
Item TypeName
Concept Prostate-Specific Antigen
Academic Article Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.
Academic Article Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
Academic Article Quantifying the amount of variation in survival explained by prostate-specific antigen.
Academic Article Novel trial designs: which agents and how do we test them?
Academic Article Editorial: States and state transitions are all that really matter.
Academic Article Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Academic Article Use of nomograms for predicting survival in patients with castrate prostate cancer.
Academic Article Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.
Academic Article Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer.
Academic Article Prostate cancer clinical trial end points: "RECIST"ing a step backwards.
Academic Article Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
Academic Article Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
Academic Article Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
Search Criteria
  • Prostate Specific Antigen